Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sho Wakasu"'
Autor:
Fumihiko Kinoshita, Tomoyoshi Takenaka, Takanori Yamashita, Koutarou Matsumoto, Yuka Oku, Yuki Ono, Sho Wakasu, Naoki Haratake, Tetsuzo Tagawa, Naoki Nakashima, Masaki Mori
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract There are great expectations for artificial intelligence (AI) in medicine. We aimed to develop an AI prognostic model for surgically resected non-small cell lung cancer (NSCLC). This study enrolled 1049 patients with pathological stage I–I
Externí odkaz:
https://doaj.org/article/345ff0637ed14dcab7eca845bdcae5cc
Autor:
Yuka Oku, Gouji Toyokawa, Sho Wakasu, Fumihiko Kinoshita, Shinkichi Takamori, Kenji Watanabe, Naoki Haratake, Taichi Nagano, Keisuke Kosai, Kazuki Takada, Airi Fujimoto, Kodo Higashijima, Yoshimasa Shiraishi, Kentaro Tanaka, Hiroaki Takeoka, Masaki Okamoto, Takanori Yamashita, Mototsugu Shimokawa, Fumihiro Shoji, Koji Yamazaki, Tatsuro Okamoto, Takashi Seto, Hitoshi Ueda, Sadanori Takeo, Naoki Nakashima, Isamu Okamoto, Tomoyoshi Takenaka, Tomoharu Yoshizumi
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14327-14336 (2023)
Abstract Background Immunotherapy has become a standard‐of‐care for patients with non‐small‐cell lung cancer (NSCLC). Although several biomarkers, such as programmed cell death‐1, have been shown to be useful in selecting patients likely to
Externí odkaz:
https://doaj.org/article/dd568051ef63481493a1e9c73bb90058
Autor:
Kazuki Takada, Shinkichi Takamori, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Fumihiko Kinoshita, Yuki Ono, Sho Wakasu, Kensuke Tanaka, Yuka Oku, Taro Oba, Atsushi Osoegawa, Tetsuzo Tagawa, Mitsuhiro Takenoyama, Mototsugu Shimokawa, Yoshinao Oda, Masaki Mori
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0241580 (2020)
Inflammatory biomarkers have been associated with clinical outcomes in non-small cell lung cancer (NSCLC). However, the best prognostic marker(s) has not been identified, and the association between inflammatory markers and clinical characteristics i
Externí odkaz:
https://doaj.org/article/afddad95e3394b87b1d032eef69e4480
Autor:
Sho Wakasu, Tetsuzo Tagawa, Naoki Haratake, Fumihiko Kinoshita, Yuka Oku, Yuki Ono, Tomoyoshi Takenaka, Yoshinao Oda, Mototsugu Shimokawa, Masaki Mori
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1823-1834
Background: Ectopic lymphoid formations are called tertiary lymphoid structures (TLSs). TLSs in cancer have been reported to be associated with good prognosis and immunotherapy response. However, the relationship between TLSs and lymph node (LN) meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e5119df1175bb88eb59b42011217f73
https://doi.org/10.1007/s00262-022-03353-8
https://doi.org/10.1007/s00262-022-03353-8
Autor:
Takanori Yamashita, Mototsugu Shimokawa, Yuka Oku, Naoki Haratake, Fumihiko Kinoshita, Keisuke Kosai, Tomoyoshi Takenaka, Yuki Ono, Naoki Nakashima, Gouji Toyokawa, Tetsuzo Tagawa, Masaki Mori, Sho Wakasu
Publikováno v:
Anticancer Research. 41:1621-1628
Background/aim Albumin-bilirubin (ALBI) grade is an indicator of liver dysfunction and is useful for predicting postoperative prognosis of hepatocellular carcinomas. However, the significance of ALBI grade in non-small cell lung carcinoma (NSCLC) has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43e0da24b20b51130e3909053f56a80b
https://doi.org/10.21873/anticanres.14924
https://doi.org/10.21873/anticanres.14924
Autor:
Fumihiko Kinoshita, Keisuke Kosai, Atsushi Osoegawa, Takaki Akamine, Masaki Mori, Kensuke Tanaka, Yuki Ono, Tetsuzo Tagawa, Taro Oba, Kazuki Takada, Tomoaki Hoshino, Yoshinao Oda, Sho Wakasu, Mototsugu Shimokawa, Yuka Oku, Yuichi Yamada
Publikováno v:
Cancer Immunology, Immunotherapy. 70:123-135
Interleukin (IL)-38 was discovered in 2001 and is a member of the IL-1 family of cytokines. IL-38 shows anti-inflammatory activity in several inflammatory diseases. In lung adenocarcinoma, we previously demonstrated that high IL-38 expression in tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e28c017f08460d1dd9557428334ce85
https://doi.org/10.1007/s00262-020-02659-9
https://doi.org/10.1007/s00262-020-02659-9
Autor:
TOMOYOSHI TAKENAKA, TETSUZO TAGAWA, MIKIHIRO KOHNO, NAOKI HARATAKE, FUMIHIKO KINOSHITA, YUKI ONO, SHO WAKASU, YUKA OKU, MASAKI MORI
Publikováno v:
Anticancer research. 42(2)
Sublobar resection is widely performed for early-stage non-small cell lung cancer in the clinical setting. This study evaluated the optimal surgical procedures of clinical stage 0 or IA adenocarcinoma from the perspective of recurrence.A total of 508
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30449cbe4cd40b4a8f88052d18724231
https://pubmed.ncbi.nlm.nih.gov/35093917
https://pubmed.ncbi.nlm.nih.gov/35093917
Autor:
Yoshinao Oda, Kensuke Tanaka, Tetsuzo Tagawa, Yuichi Yamada, Atsushi Osoegawa, Taro Oba, Keisuke Kosai, Kazuki Takada, Fumihiko Kinoshita, Yuki Ono, Mototsugu Shimokawa, Yuka Oku, Masaki Mori, Sho Wakasu
Publikováno v:
Annals of Surgical Oncology. 27:2102-2109
Immunotherapy has become a standard treatment option for non-small cell lung cancer (NSCLC), with the tumor microenvironment attracting significant attention. CD8 + and forkhead box protein P3 + (FoxP3 +) tumor-infiltrating lymphocytes (TILs) influen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8b369b2c187e6dba071c3bfb79e286d
https://doi.org/10.1245/s10434-019-08029-9
https://doi.org/10.1245/s10434-019-08029-9
Autor:
Kazuki Takada, Akira Haro, Sho Wakasu, Atsushi Osoegawa, Masaki Mori, Takeshi Kamitani, Tetsuzo Tagawa
Publikováno v:
International Journal of Surgery Case Reports
Highlights • Most of pulmonary metastasis present as a well-defined solid and round nodule. • This is the rare case of a pulmonary metastasis presenting as a ground glass opacity-like lesion with a thin-walled cavity of tongue cancer. • The pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b7f72c1673a4dfcf4bffcb083bf967
https://doi.org/10.1016/j.ijscr.2019.06.030
https://doi.org/10.1016/j.ijscr.2019.06.030
Autor:
Yuka Oku, Gouji Toyokawa, Takanori Yamashita, Sho Wakasu, Fumihiko Kinoshita, Shinkichi Takamori, Naoki Haratake, Yoshimasa Shiraishi, Mototsugu Shimokawa, Koji Yamazaki, Tatsuro Okamoto, Naoki Nakashima, Isamu Okamoto, Tomoyoshi Takenaka
Publikováno v:
Journal of Clinical Oncology. 40:e21125-e21125
e21125 Background: In recent years, there have been expectations for the application of artificial intelligence (AI) in the clinical practice of lung cancer. In the first-line setting, immune checkpoint inhibitors (ICIs) in combination with cytotoxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::634808d2381593f43bd12f3b3201a7ff
https://doi.org/10.1200/jco.2022.40.16_suppl.e21125
https://doi.org/10.1200/jco.2022.40.16_suppl.e21125